|Articles|March 1, 2018
- Pharmaceutical Executive-03-01-2018
- Volume 38
- Issue 3
Pharmaceutical Executive, March 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Pharma: Meet Your New Neighborsabout 8 years ago
Risk Sharing, Italian Styleabout 8 years ago
The Quest to Measure Upabout 8 years ago
Full Disclosure Demanded for Pharma Industryabout 8 years ago
Setting the Standard: William Soliman, ACMAabout 8 years ago
The Law of Unintended Consequencesabout 8 years ago
Pricing Turning Point: The Case for Innovating Pharma’s Modelabout 8 years ago
Showdown Nears on Europe Research Incentivesabout 8 years ago
The Personalized Genetic Profile: It’s Time to Alignabout 8 years ago
Country Report: IndiaAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?
2
The Evolving Relationship Between FDA and Biotech
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
5